Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From NeoTract, Inc.
Urology device developer NeoTract, which Teleflex purchased in 2017, is now under scrutiny for potential FCA violations.
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Landmark studies of newer techniques have led the American Urological Association to update its guidelines.
The medical technology industry was a solid if tricky bet for investors in 2017, and will be so in 2018. That is the view of Jefferies Healthcare US-based equity analyst Raj Denhoy. Speaking to In Vivo during the group's London meeting in fall 2017, he gave context to the motivations and drivers of medtechs large and small for 2018 and beyond.
Third-quarter device financing at $2.38 billion – almost half of that amount from CooperSurgical's $1.1 billion bridge loan – was double the Q2 total, while device acquisitions showed a steep decrease at $3.38 billion versus Q2's $33.4 billion. Diagnostics fundraising also was up in the third quarter, reaching $2.4 billion (a 133% increase over Q2) mostly from Thermo Fisher Scientific's $1.5 billion follow-on offering, which accounted for 63% of the total. In line with the previous quarter's $1.7 billion in M&A, Q3 diagnostics acquisitions had an aggregate value of $1.8 billion, led by Konica Minolta's $1 billion buy of Ambry Genetics.
- Implantable Devices
Surgical Equipment & Devices
- Minimally or Less Invasive